Top Story

FDA grants 'breakthrough' status to EBV-CTL for EBV-associated lymphoproliferative disease

March 2, 2015

The FDA today granted breakthrough therapy designation to EBV-CTL for the treatment of patients with rituximab-refractory, Epstein-Barr virus-associated lymphoproliferative disease, according to a press release from the drug’s manufacturer.

Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) is a malignancy that occurs after allogeneic hematopoietic cell transplantation.

Meeting News Coverage

HIV did not affect HCC recurrence or survival after LT

March 2, 2015
Survival and recurrence rates were unaffected by HIV infection among patients who underwent liver transplantation for hepatocellular carcinoma, according to a poster…
Industry News

Novartis completes acquisition of GSK oncology portfolio

March 2, 2015
Novartis completed its acquisition of GlaxoSmithKline’s oncology portfolio for an aggregate cash consideration of $16 billion, the companies announced…

Boehringer Ingelheim files BLA for antidote to dabigatran

March 2, 2015
Boehringer Ingelheim announced that it has submitted a biologics license application to the FDA requesting an accelerated approval pathway for idarucizumab, an antidote…
In the Journals

Chronic fungal lesions predisposed to malignancy

March 2, 2015
Researchers in Brazil documented seven cases of squamous cell carcinoma that resulted from chronic chromoblastomycosis in the Brazilian Amazon state…
More News Headlines »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Video
thumbnail for video 4040847621001

MET targeting, PD-L1/PD-1 inhibition highlight recent developments in genitourinary oncology

February 11, 2015
Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, president of Levine Cancer Institute at Carolinas HealthCare System and…
More »
CME
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »